Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2014 5
2015 12
2016 41
2017 26
2018 25
2019 55
2020 50
2021 50
2022 53
2023 65
2024 51

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Results by year

Filters applied: . Clear all
Page 1
Andexanet Alfa and its Clinical Application.
Noordergraaf FA, Alings M. Noordergraaf FA, et al. Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020. Heart Int. 2020. PMID: 36277667 Free PMC article. Review.
This review will discuss andexanet alfa's mode of action, indication for use and efficacy, with a focus on its appropriate use in clinical practice. ...Assessment of potentially suitable patients by a multidisciplinary team, use according to the institutional protoc …
This review will discuss andexanet alfa's mode of action, indication for use and efficacy, with a focus on its appropriate use …
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B, Coleman CI. Costa OS, et al. Crit Care. 2022 Jun 16;26(1):180. doi: 10.1186/s13054-022-04043-8. Crit Care. 2022. PMID: 35710578 Free PMC article.
BACKGROUND: Andexanet alfa is approved (FDA "accelerated approval"; EMA "conditional approval") as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding. ...Two thrombotic events occurred with andexan …
BACKGROUND: Andexanet alfa is approved (FDA "accelerated approval"; EMA "conditional approval") as the first specific reversal …
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ Jr, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, Verhamme P, Cohen AT, Beyer-Westendorf J, Gibson CM, Lopez-Sendon J, Crowther M, Shoamanesh A, Coppens M, Schmidt J, Albaladejo P, Connolly SJ; ANNEXA-4 Investigators. Milling TJ Jr, et al. Circulation. 2023 Mar 28;147(13):1026-1038. doi: 10.1161/CIRCULATIONAHA.121.057844. Epub 2023 Feb 20. Circulation. 2023. PMID: 36802876 Free article. Clinical Trial.
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3 …
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 ( …
Andexanet alfa for the treatment of hemorrhage.
Cervi A, Crowther M. Cervi A, et al. Expert Rev Hematol. 2018 Nov;11(11):847-855. doi: 10.1080/17474086.2018.1532287. Epub 2018 Oct 17. Expert Rev Hematol. 2018. PMID: 30296870 Review.
While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among cli …
While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K ant …
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators. Connolly SJ, et al. N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7. N Engl J Med. 2019. PMID: 30730782 Free PMC article.
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. ...
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhi …
Andexanet Alfa: First Global Approval.
Heo YA. Heo YA. Drugs. 2018 Jul;78(10):1049-1055. doi: 10.1007/s40265-018-0940-4. Drugs. 2018. PMID: 29926311 Free PMC article. Review.
Intravenous andexanet alfa is under regulatory review in the EU and is undergoing clinical development in Japan. This article summarizes the milestones in the development of andexanet alfa leading to this first global approval for reversing anticoagula …
Intravenous andexanet alfa is under regulatory review in the EU and is undergoing clinical development in Japan. This article …
Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
Powell J, Taylor J, Garland SG. Powell J, et al. Ann Pharmacother. 2019 Sep;53(9):940-946. doi: 10.1177/1060028019835209. Epub 2019 Feb 27. Ann Pharmacother. 2019. PMID: 30813754 Review.
Objective: The purpose of this article is to review the available clinical trial data for andexanet alfa and its role in clinical practice. Data Sources: A MEDLINE/PubMed search was conducted (January 2000 to January 2019) using the keyword andexanet alfa …
Objective: The purpose of this article is to review the available clinical trial data for andexanet alfa and its role in clini …
Andexanet alfa for the reversal of factor Xa inhibitors.
Favresse J, Hardy M, van Dievoet MA, Sennesael AL, Douxfils J, Samama CM, Vornicu O, Dincq AS, Lessire S, Mullier F. Favresse J, et al. Expert Opin Biol Ther. 2019 May;19(5):387-397. doi: 10.1080/14712598.2019.1599355. Epub 2019 Apr 11. Expert Opin Biol Ther. 2019. PMID: 30974977 Review.
Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. ...Well-designed studies comparing the efficacy and safety of andexanet alfa to other reversal strategies are required to confirm prelim …
Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. ...Well-de …
Andexanet Alfa.
Reed M, Tadi P, Nicolas D. Reed M, et al. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30137783 Free Books & Documents.
Andexanet alfa is a recombinant modified Factor Xa protein approved by the FDA in May 2018 to reverse apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding. ...This activity will highlight the mechanism of action, adverse event profile, …
Andexanet alfa is a recombinant modified Factor Xa protein approved by the FDA in May 2018 to reverse apixaban and rivaroxaban …
Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.
Carpenter E, Singh D, Dietrich E, Gums J. Carpenter E, et al. Ther Adv Drug Saf. 2019 Nov 26;10:2042098619888133. doi: 10.1177/2042098619888133. eCollection 2019. Ther Adv Drug Saf. 2019. PMID: 31807265 Free PMC article. Review.
BACKGROUND: Review of clinical data on andexanet alfa for the reversal of factor Xa (FXa) inhibitor associated anticoagulation. ...Furthermore, anticoagulation should be resumed following the administration of andexanet alfa as soon as medically approp …
BACKGROUND: Review of clinical data on andexanet alfa for the reversal of factor Xa (FXa) inhibitor associated anticoagulation …
376 results